|
Pharmexcil urges member exporters to respond to Mauritius medicine requirement
|
|
Shardul Nautiyal, Mumbai
July 12 , 2025
|
|
|
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has issued a call to its member exporters, urging them to respond promptly to a request from the ministry of health & wellness, Government of Mauritius. The appeal follows a communication received from the High Commission of Mauritius in New Delhi regarding the urgent requirement of various medicines.
Pharmexcil has highlighted that Mauritius is seeking pharmaceutical supplies and has shared a detailed list of required medicines for consideration. Companies possessing approvals from Stringent Regulatory Authorities (SRA) or the Mauritius FDA are encouraged to participate.
Pharmexcil director general Raja Bhanu stated, “We are pleased to facilitate this important international cooperation. Member exporters manufacturing the listed products and meeting the regulatory requirements are urged to express their interest by submitting details through the designated Google form at the earliest.”
Pharmexcil emphasized the importance of timely response to ensure effective onward communication of supplier details to the High Commission of Mauritius. This initiative represents a valuable opportunity for Indian pharmaceutical exporters to support global health efforts while strengthening bilateral ties with Mauritius.
Medicines required are used in the treatment of leprosy, treatment prevention and relapse of malaria, to treat and prevent tuberculosis (TB), asthma, bacterial infections of the eyes and skin and treat infection or inflammation of the ear or eye among others.
Medicines include dapsone 50mg tablet, clofazimine tablet, mefloquine HCL 250mg tablet, primaquine phosphate 15mg tablet, isonicotinic acid hydrazide 100mg tablet, rifampicin 150mg + isoniazid 75mg tablet, rifampicin tablet, bedaquiline 100mg tablet, sulphadiazine 500mg tablet, ethionamide 250mg tab, nevirapine solution, framycetin sulphate 0.5% + dexamethasone 0.05% eye drops and beclomethasone nasal spray among other 40 medicines.
The supplier should have a marketing authorisation in the country of origin. Manufacturer should submit document to certify that the product has been manufactured and registered at the Regulatory Authority Agency of the country of origin. The Pharmaceutical Products offered should be registered in the Pharmacy Board of Mauritius, in GCC Countries or in PIC Countries.
Products registered in Non (Pharmaceutical Inspection Co-operation Scheme) PIC countries may also be considered provided that manufacturer is listed with Central Drug Standard Control Organisation (CDSCO) and product is from manufacturers whose manufacturing sites are present on WHO Public Inspection Report (WHOPIR), EUDRA (MHRA) and US FDA.
PICS is an international agreement between regulatory authorities that focuses on Good Manufacturing Practice (GMP) for pharmaceuticals. It aims to harmonize GMP standards and facilitate mutual recognition of inspections among participating countries.
As per the regulatory guidelines, the pharmaceutical products should also be registered with either:-(1). European Medicines Agency (EMA) or in any country of the European Union (EU) zone; or (2). Australian Therapeutic Goods Administration (Australian TGA); or (3) United State Food and Drug Administration (USFDA); or (4) South African Health Products Regulatory Authority (SAHPRA); or (5) Health Canada; or (6) Singapore Health Sciences Authority (Singapore HSA); or (7) Central Drug Standard Control Organisation (CDSCO) - India.
The following documents should be submitted, as applicable: a. Valid individual Certificate of Pharmaceutical Products (CoPP) for each product, b. A free Sale Certificate, c. Certificate of Analysis (CoA) at time of delivery (d) Package insert to be in English (e) Shelf life should be 75% to 80% of total shelf life of product at time of delivery (f) Delivery should be from Ex-Stock and within one week from date of award (g) To be dispatched by air and delivery should be on a Cost, Insurance, and Freight (CIF) basis.
|
|
|
|
|
|
|
|
TOPICS
|
Shanghai-based Hualian Pharmaceutical Machinery Company Limited, a family-run enterprise with roots going back to 1986, ...
|
|
|
|
|